Prolame produces anxiolytic- and antidepressant-like effects in middle-aged female rats with less uterotrophic effects than 17 β-estradiol
This study aimed to identify the antidepressant- and anxiolytic-like effects of prolame and E2 (used as a reference estrogen treatment) in middle-aged female rats coursing with irregular cycles, in two different conditions: ovariectomized or gonadally intact. Results were compared with those from young adult ovariectomized rats. Prolame (60 or 120 μg/kg), 17β-estradiol (E2, 40 or 80 μg/kg), or vehicle were chronically administered, and their effects were evaluated in the elevated plus-maze, defensive burying behavior test, open field test, and forced swimming test. Uterotrophic actions were estimated by uterine weight r...
Source: European Journal of Pharmacology - February 28, 2024 Category: Drugs & Pharmacology Authors: C Lemini E Garc ía-Albor B Cruz-L ópez G Matamoros-Trejo S M árquez-Baltazar J J Herrera-P érez L Mart ínez-Mota Source Type: research
Drug repurposing screen identifies novel anti-inflammatory activity of sunitinib in macrophages
This study validates drug repurposing as a strategy for the identification of novel anti-inflammatory medicines and highlights sunitinib as a potential drug repurposing candidate for inflammatory disease via inhibition of NF-κB signalling.PMID:38417608 | DOI:10.1016/j.ejphar.2024.176437 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 28, 2024 Category: Drugs & Pharmacology Authors: Laura E Chaffey Annabell Roberti Amelia Bowman Conan Jo O'Brien Liliana Som Gareth Sd Purvis David R Greaves Source Type: research
Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent advances
Eur J Pharmacol. 2024 Feb 26:176452. doi: 10.1016/j.ejphar.2024.176452. Online ahead of print.ABSTRACTSeeking an effective and safe scheme is the common goal of clinical treatment of tumor patients. In recent years, traditional Chinese medicine has attracted more and more attention in order to discover new drugs with good anti-tumor effects. Oroxylin A (OA) is a compound found in natural Oroxylum indicum and Scutellaria baicalensis Georgi plants and has been used in the treatment of various cancers. Studies have shown that OA has a wide range of powerful biological activities and plays an important role in neuroprotection,...
Source: European Journal of Pharmacology - February 28, 2024 Category: Drugs & Pharmacology Authors: Peng-Xin Wang Xiao-Nan Mu Shu-Hong Huang Kang Hu Zhi-Gang Sun Source Type: research
Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu
In conclusion, Tyr effectively reduced NASH-related steatosis, fibrosis, oxidative stress, and inflammation, displaying a beneficial effect on the hepatic immune infiltrate, indicating its possible development as a therapeutic agent for NASH due to its multifaceted mechanism.PMID:38408597 | DOI:10.1016/j.ejphar.2024.176453 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Authors: Daniela Gabbia Katia Sayaf Ilaria Zanotto Martina Colognesi Yahima Frion-Herrera Maria Carrara Francesco Paolo Russo Sara De Martin Source Type: research
A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way
Eur J Pharmacol. 2024 Feb 24:176451. doi: 10.1016/j.ejphar.2024.176451. Online ahead of print.ABSTRACTPancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5-8 years, there has...
Source: European Journal of Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Authors: Pankti C Balar Vasso Apostolopoulos Vivek P Chavda Source Type: research
Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu
In conclusion, Tyr effectively reduced NASH-related steatosis, fibrosis, oxidative stress, and inflammation, displaying a beneficial effect on the hepatic immune infiltrate, indicating its possible development as a therapeutic agent for NASH due to its multifaceted mechanism.PMID:38408597 | DOI:10.1016/j.ejphar.2024.176453 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Authors: Daniela Gabbia Katia Sayaf Ilaria Zanotto Martina Colognesi Yahima Frion-Herrera Maria Carrara Francesco Paolo Russo Sara De Martin Source Type: research
A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way
Eur J Pharmacol. 2024 Feb 24:176451. doi: 10.1016/j.ejphar.2024.176451. Online ahead of print.ABSTRACTPancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5-8 years, there has...
Source: European Journal of Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Authors: Pankti C Balar Vasso Apostolopoulos Vivek P Chavda Source Type: research
The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPAR α/γ activity
In this study, our objective was to examine the effects of phenolic extracts derived from Magnolia officinalis on the regulation of NAFLD. Specifically, we investigated the impact of Magnolol or Honokiol treatment on high-fat diet (HFD)-induced obese C57BL6/J male mice. Firstly, we monitored energy metabolism, dissected tissues, and analyzed tissue sections. Additionally, we conducted experiments on HepG2 and primary adipocytes to gain insights into the roles of Magnolol or Honokiol. To further understand the effects of these compounds on related signaling pathways and marker genes, we performed molecular docking, dual-luc...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Yi Chu Sisi Gui Yazhen Zheng Jingwu Zhao Yaxiang Zhao Yingying Li Xiaodong Chen Source Type: research
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet
This study investigated the effects of Semaglutide (sema) on the gut microbiota of obese mice induced with high-fat diet (HFD). Male C57BL/6 J mice aged 6 weeks were enrolled and randomly distributed to four groups, which were provided with a normal control diet (NCD,NCD + Sema) and a 60% proportion of a high-fat diet (HFD,HFD + Sema), respectively. HFD was given for 10 weeks to develop an obesity model and the intervention was lasted for 18 days. The results showed Semaglutide significantly reduced body weight gain, areas under the curve (AUC) of glucose tolerance test and insulin resistance test, as well as adipose tissu...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Xinhao Duan Lei Zhang Yi Liao Zijing Lin Changxin Guo Sen Luo Fu Wang Zhen Zou Zhijun Zeng Chengzhi Chen Jingfu Qiu Source Type: research
Demotion of canonical/non-canonical inflammasome and pyroptosis alleviates ischemia/reperfusion-induced acute kidney injury: Novel role of the D2/D3 receptor agonist ropinirole
In conclusion, ropinirole has the potential to be a reno-therapeutic treatment against I/R insult by abating the inflammatory NLRP3 inflammasome signal, pyroptosis, and oxidative stress.PMID:38402931 | DOI:10.1016/j.ejphar.2024.176460 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Nada T Henedak Hanan S El-Abhar Dalaal M Abdallah Kawkab A Ahmed Ayman A Soubh Source Type: research
The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPAR α/γ activity
In this study, our objective was to examine the effects of phenolic extracts derived from Magnolia officinalis on the regulation of NAFLD. Specifically, we investigated the impact of Magnolol or Honokiol treatment on high-fat diet (HFD)-induced obese C57BL6/J male mice. Firstly, we monitored energy metabolism, dissected tissues, and analyzed tissue sections. Additionally, we conducted experiments on HepG2 and primary adipocytes to gain insights into the roles of Magnolol or Honokiol. To further understand the effects of these compounds on related signaling pathways and marker genes, we performed molecular docking, dual-luc...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Yi Chu Sisi Gui Yazhen Zheng Jingwu Zhao Yaxiang Zhao Yingying Li Xiaodong Chen Source Type: research
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet
This study investigated the effects of Semaglutide (sema) on the gut microbiota of obese mice induced with high-fat diet (HFD). Male C57BL/6 J mice aged 6 weeks were enrolled and randomly distributed to four groups, which were provided with a normal control diet (NCD,NCD + Sema) and a 60% proportion of a high-fat diet (HFD,HFD + Sema), respectively. HFD was given for 10 weeks to develop an obesity model and the intervention was lasted for 18 days. The results showed Semaglutide significantly reduced body weight gain, areas under the curve (AUC) of glucose tolerance test and insulin resistance test, as well as adipose tissu...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Xinhao Duan Lei Zhang Yi Liao Zijing Lin Changxin Guo Sen Luo Fu Wang Zhen Zou Zhijun Zeng Chengzhi Chen Jingfu Qiu Source Type: research
Demotion of canonical/non-canonical inflammasome and pyroptosis alleviates ischemia/reperfusion-induced acute kidney injury: Novel role of the D2/D3 receptor agonist ropinirole
In conclusion, ropinirole has the potential to be a reno-therapeutic treatment against I/R insult by abating the inflammatory NLRP3 inflammasome signal, pyroptosis, and oxidative stress.PMID:38402931 | DOI:10.1016/j.ejphar.2024.176460 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Nada T Henedak Hanan S El-Abhar Dalaal M Abdallah Kawkab A Ahmed Ayman A Soubh Source Type: research
